This Little-Known Biotech Company is Quickly Becoming a Paramount Player in the Mental Health Industry

Learn about how this company could also become a major disruptor in the market for medical psychedelics.

Research by Tim Collins and Bob Byrne of Streetlight Equity

July 20, 2021

Watch this brief video to get the exciting story or keep reading for the five surprising reasons this company could bring you windfall profits:

This video reveals how a little-known company’s breakthrough medical psychedelics could ease the suffering of the 704 million people who suffer from mental disorders and become a global leader in its field. Watch it now or read below for all five surprising reasons this company’s stock could be a big winner.

One little-known biotech company could be the next big winner when investors realize how close it is to revolutionizing the market for psychotropic drugs used to treat mental health disorders. We’re going to help you get a jump on other investors by explaining how this company’s cutting-edge compounds and breakthrough manufacturing process could improve the lives of 704 million people and the wealth of the its shareholders. Right now, select biotech stocks are generating spectacular returns.

Just look at this:

Year-to-date gain

(calculated to May 4, 2021)
  • KemPharm, Inc. [KMPH] ……………………………………… 1,177.78%
  • Acorda Therapeutics, Inc. [ACOR] …………………………….. 84%
  • Moleculin Biotech, Inc. [MBRX] …………………………………. 60%
  • Pandion Therapeutics, Inc. [PAND] …………………………… 38%
  • Acaris Therapeutics, Inc. [ACRS] ……………………………….. 84%
  • Intrexon Corporation [XON] …………………………………….. 99%
  • Rubius Therapeutics, Inc. [RUBY] ……………………………… 39%
  • IntelGenx Technologies Corp. [IGXT] ………………………… 36%
  • Entera Bio Ltd. [ENTX] ………………………………………………. 11%
  • Sunesis Pharmaceuticals, Inc. [SNSS] ………………………… 34%

Year-to-date gain

(calculated to May 4, 2021)
  • KemPharm, Inc. [KMPH] …1,177.78%
  • Acorda Therapeutics, Inc. [ACOR] …84%
  • Moleculin Biotech, Inc. [MBRX] …. 60%
  • Pandion Therapeutics, Inc. [PAND] … 38%
  • Acaris Therapeutics, Inc. [ACRS] … 84%
  • Intrexon Corporation [XON] … 99%
  • Rubius Therapeutics, Inc. [RUBY] … 39%
  • IntelGenx Technologies Corp. [IGXT] … 36%
  • Entera Bio Ltd. [ENTX] … 11%
  • Sunesis Pharmaceuticals, Inc. [SNSS] … 34%

Mindset Pharma (OTC: MSSTF / CSE: MSET) could soon be on that list.

That’s why we wrote the research report called Mindset Pharma and The Psychotropic Drug Revolution, which we would like to send you today. And why we’re about to reveal the 6 reasons to invest in Mindset today.

Before we share those reasons, let me introduce myself. My name is Bob Byrne. I’ve been a trader since my sophomore year in college. In 2005, I made one billion dollars’ worth of trades. In 2006, that number doubled. Today, my business partner Tim Collins – whose firm bought Facebook and Twitter in the early 2010’s before they were public companies – and I operate Streetlight Equity. Our mission, the reason we wake up in the morning, is to provide everyday investors – you – an edge in the markets. We talk to company CEOs, CFOs, watch stock charts and identify the early stages of big trends to make you money.  And we publish the best investments we can find in our newsletter.

Our latest find is Mindset Pharma. Here’s why we believe this investment could potentially mint new fortune: A $45 billion market. The market for psychotropic drugs is enormous. Annual sales, currently $27 billion, are projected to soar to $45 billion by 2025.

 Reason #1: Psilocybin Treats Depression and Other Illnesses Better
Than Any Other Pharmaceuticals Currently Available in Clinical Trials

Psilocybin is the substance derived from mushrooms and studies show it treats an amazingly wide range of psychiatric and neurological conditions better than current medications, including:

  • Depression
  • Anxiety
  • PTSD (Post Traumatic Stress Disorder)
  • Alcohol and drug addiction
  • Alzheimer’s disease
  • ADHD
  • Traumatic brain injury
  • Neuropathic pain
  • End-of-life angst

And that’s where Mindset Pharma (OTC: MSSTF / CSE: MSET) enters the picture and not only offers 704 million people a new, better chance at relief from depression, anxiety and other mental ailments, but also investors the chance at potentially eye-popping profits.

Reason #2: Mindset Pharma creates a better psilocybin

Despite its efficacy, psilocybin has drawbacks, which Mindset has overcome. For one, psilocybin is a somewhat “messy” drug. It breaks down into a number of different compounds in the body, only one of which (psilocin) has therapeutic value.

The “byproduct” compounds provide no benefit to the patient and create the possibility of toxic side effects. In fact, patients who take other prescription drugs as well as psilocybin are almost guaranteed to experience side effects since these byproduct compounds tend to interact with other medications.

Mindset has overcome the purity problem by developing a patent-pending process for creating a synthetic psilocybin in the laboratory that has all the benefits of the compound extracted from mushrooms, but without any of the side effects.

Mindset isn’t the first company to produce a synthetic psilocybin. However, it has a synthesis process that gives it a huge competitive advantage.

Reason #3: Mindset makes psilocybin affordable

According to Matthew Johnson, a professor at John Hopkins University who has conducted extensive research, pharmaceutical grade psilocybin costs between $7,000 and $10,000 per gram.

The conventional approach is so expensive because the people doing the work, the chemistry procedures used to synthesize the compound, the purity of pre-cursors, and the equipment used in the manufacturing process all have to meet exacting FDA standards. Mindset has cleverly devised a way to combine some of the steps in this extremely complicated process.

The company’s patent-pending methodology still complies with FDA regulations, but radically reduces production costs. And it’s scalable, meaning it can be used to produce psilocybin in commercial quantities without losing the cost advantage. During a recent conversation, Joseph Araujo, Mindset’s Chief Scientific Officer, told us that this new approach allows the company to produce psilocybin for “hundreds, not thousands of dollars.” Even at $1,000, Mindset’s cost would be just 10% to 14.2% of what it costs competitors to produce psilocybin. And slashing the cost of a key drug component by 90% is usually a sure path to outsized profits.

This means it could sell its products for less than other companies and could thus grab more market share faster. However valuable this synthesis process is, what the company is doing with it could turn out to be even more valuable.

    Reason #4: Multiple ways to profit

    Mindset is using its patent-pending synthesis process to create not just one drug candidate, but over 75 different psilocybin based compounds, divided into two different groups:

    The Macro dosing compounds are designed to work quickly, but to wear off quickly as well. This type of drug must be administered in a medical facility.

    The Micro dosing compounds are designed to be taken regularly in small doses. The lower dosage provides therapeutic results without causing a hallucinogenic experience, which is one of the reasons psychedelic drugs got such a bad rep for a while. Because these drugs have a longer duration, they benefit the patient throughout the day. Micro dosing is the preferred approach for treating, for example, ADHD in children where a hallucinogenic experience is undesirable.

    The company’s psilocybin-based compounds have undergone successful in vitro and in vivo testing. And selected candidates are now ready for the next step on the road to eventual FDA approval.

    In addition to its psilocybin-based compounds, Mindset is researching drugs based on DMT and 5-MeO-DMT. These naturally occurring chemicals found in many plants have a chemical structure similar to tryptamine, a close cousin of dopamine
    and serotonin.

       Reason #5: Everything that makes a small-cap biotech stock so profitable

      In addition to promising research (and more to come), Mindset Pharma has all of the things we look for in a small-cap biotech stock:

      • Patent-protected intellectual property (over 75 psilocybin-based drug candidates, plus an additional amounts based on DMT and 5-MeO-DMT)
      • A huge potential market (704 million people!)
      • Sufficient cash to fund research ($8.5 million to fund development)
      • Solid management and an extremely talented science team
      • A competitive edge (a synthesis process that slashes costs 90%)

      Our new Special Report, Mindset Pharma and The Psychotropic Drug Revolution, is a good place to start your own due diligence research. It’s one of  4 Special Reports (a combined $99 value) you’ll receive with a no-risk trial subscription to Streetlight Equity’s online newsletter.


      Each issue of Streetlight Equity newsletter brings you:

      • In-depth fundamental and technical analysis of our favorite stock that month and how to position yourself for maximum profit. In our feature article each month, you’ll get the whole story behind the company. What they do, what’s their competitive advantage in the industry, why they’re positioned to see big growth and the steps you need to take next to profit.
      • Our forecast for the economy, the political climate, and their impact on the markets. If you ignore these important factors, you’re leaving money on the table.
      • Long term investment ideas to create a powerful and profitable foundation for your portfolio. We identified marijuana as an investment opportunity back in 2014 when it was just a budding industry… we see similar opportunities in the psilocybin market today.
      • Short term stock ideas that can bring you even quicker profits if you’re a more aggressive investor.

      Save 60% and receive 4 FREE Special Reports

      A six month subscription to Streetlight Equity newsletter is just $39 — a 60% discount off the regular price. Plus, if you subscribe for a full year today at $74, you’ll also receive up to four FREE Special Reports valued at $79.20.

      • FREE Special Report #1: Mindset Pharma and The Psychotropic Drug Revolution (a $19.80 value)
      • FREE Special Report #2: 3 Stocks Potentially Set to Skyrocket to 300% or More (a $19.80 value)
      • FREE Special Report #3: 4 Steps to Trade Like a Pro (a $19.80 value)

      And if you respond within 10 days, you’ll receive an extra FREE Special Report:

      • FREE Special Report #4: 2 Little Known Microcap Stocks Poised to Explode in 2021 (a $19.80 value )

      Your trial subscription is risk-free because you’re fully protected by…

      Our Money-Back Triple Guarantee

      You must be 100% satisfied with the ideas and strategies you’ll find in the Streetlight Equity newsletter.

      GUARANTEE #1: If you’re dissatisfied for any reason, let us know within 30 days and we’ll send you a full refund of every penny you paid.

      GUARANTEE #2: In the unlikely event you cancel your subscription, you may keep all the Special Reports you received, as well as any issues of the newsletter.

      GUARANTEE #3: If you cancel after 30 days, we’ll send you a pro rata refund for the remaining balance of your subscription. And, again, you may keep all the Special Reports and issues you received.

      It’s easy to get started

      To get started with your risk-free trial subscription to Streetlight Equtiy, simply pick up the phone and call Toll-Free 1-888-638-8017.

      Regardless of what you decide about subscribing, do your research to confirm what you’ve read in these pages, and then add some shares of Mindset Pharma to your portfolio. A few months from now we think you’ll be glad you did.

      Research by Tim Collins and Bob Byrne of Streetlight Equity

      July 20, 2021

      NO INVESTMENT ADVICE IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This paid advertisement includes a stock profile of Mindset Pharma (OTC:MSSTF). Streetlight Equity is an investment newsletter being advertised herein. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to buy or sell, or as a solicitation to buy or sell, any securities. In an effort to enhance public awareness of (OTC:MSSTF), provided advertising agencies with a total budget of approximately one $1,606,579 dollars to cover the costs associated with creating, printing and distribution of this advertisement August 02, 2021 – October 30, 2021. Payor has represented to advertising agencies in writing that this advertising campaign is funded by OTC:MSSTF, to be profiled in this advertisement after Streetlight Equity conducted an investigation of the company and its management. Streetlight Equity was paid thirty-five thousand dollars as a research fee. In addition, Streetlight Equity may receive subscription revenue in the future from new subscribers as a result of this advertisement. The advertising agencies will retain any excess sums after all expenses are paid. During the period of time this advertisement is being disseminated, neither Streetlight Equity, the advertising agencies, nor their respective officers, principals, or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) and will, receive or sell such securities of Mindset Pharma. for not less than 90 days following the conclusion of this advertising campaign. The Payor has represented in writing to Streetlight Equity and the advertising agencies that neither it nor its officers, principals, or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) owns or beneficially owns any securities of the OTC:MSSTF or will purchase, receive, or sell any such securities for not less than 90 days following the conclusion of this advertising campaign. If successful, this advertisement will increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of OTC:MSSTF, increased trading volume, and possibly an increased share price of OTC:MSSTF securities, which may be temporary. This advertisement, the advertising agencies and Streetlight Equity do not purport to provide a complete analysis of OTC:MSSTF’s financial position. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell and only after reviewing the financial statements and other pertinent publicly-available information about OTC:MSSTF and its industry. Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in OTC:MSSTF SEC filings. Investing in microcap securities such as OTC:MSSTF is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agencies and Streetlight Equity cannot guarantee the accuracy or completeness of the information and are not responsible for any errors or omissions. This advertisement contains forward-looking statements, including statements regarding expected continual growth of OTC:MSSTF and/or their industry. The advertising agencies and Streetlight Equity note that statements contained herein that look forward in time, which include everything other that historical information, involve risks and uncertainties that may affect OTC:MSSTF actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for OTC:MSSTF products and/or services, the company’s ability to fund its capital requirements in the near term and long term, Federal and state regulatory issues pricing pressures, etc. Streetlight Equity is the publisher’s trademark. All trademarks used in this advertisement other than Streetlight Equity are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agencies and Streetlight Equity are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.